New Drug: Telisotuzumab vedotin for cMET Amplified NSCLC

Phase 2, non-randomized, multicenter study (LUMINOSITY)

Previously treated c-Met overexpressing NSQ EGFR wildtype advanced NSCLC (≤2 prior lines, ≤1 chemo)

Telisotuzumab vedotin 1.9 mg/kg IV every 2 wks

ORR: 34.6% vs. 22.9% (c-Met high vs. c-Met intermediate)

mDoR: 9.0 mos vs. 7.2 mos (c-Met high vs. c-Met intermediate)

mOS: 14.6 mos vs. 14.2 mos

Any-grade TRAEs: peripheral sensory neuropathy (30%), peripheral edema (16%), fatigue (14%)

Grade 5 TRAEs: 2 pts (interstitial lung disease, respiratory failure)

Reviewed by Ulas D. Bayraktar, MD on Jun 9, 2025